Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer Seven-year results from the ...

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer. Seven-year results from the ...

Under relentless wind and rain, Tony and Bernie scramble to set up tarp and tent on a mountain ridge. Between shivering fingers, wild gusts, and soaked layers, they test gear, get water from a tarn, ...

INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY), a prominent player in the pharmaceutical industry with a market capitalization of $748 billion, will present the primary overall survival analysis from ...

Eli Lilly's CDK4/6 inhibitor Verzenio reduced the risk of death by 15.8% when used as adjuvant treatment for early-stage HR-positive, HER2-negative breast cancer, according the reveal of data from the ...

Eli Lilly’s Verzenio (abemaciclib) boosted overall survival (OS) in the adjuvant breast cancer setting during a late-stage trial. In the Phase III monarchE study, (NCT02763566), Verzenio plus ...

Original music by Dan Powell Elisheba Ittoop Marion Lozano and Diane Wong Broadway represents some of the best and most exciting of what American theater has to offer. But for many people, it’s ...